Clearstead Trust’s Arcus Biosciences RCUS Stock Holding History

Clearstead Trust’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27	Closed	-$368	–	1420
2025 Q3	$368	Hold	27	–	–	﹤0.01%	1424
2025 Q2	$220	Buy	+27	New	+$231	﹤0.01%	1463

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Clearstead Trust's RCUS Position: Q4 2025 in Review

Clearstead Trust sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 27 shares — an estimated $368 sold.

Clearstead Trust first reported a position in RCUS in Q2 2025 and held it in 2 quarters. The position peaked at $368 in Q3 2025. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

Clearstead Trust reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
Clearstead Trust sold 27 Arcus Biosciences shares in Q4 2025, an estimated $368.
Clearstead Trust first reported a position in Arcus Biosciences in Q2 2025 and held it in 2 quarters.
Clearstead Trust's Arcus Biosciences position peaked at $368 in Q3 2025.
209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Clearstead Trust's 13F filing for Q4 2025, filed 9 Feb 2026.